Adjuvants targeting innate and adaptive immunity synergize to enhance tumor immunotherapy

Proceedings of the National Academy of Sciences of the United States of America

Volumn 105, Issue 43, 2008, Pages 16683-16688

  Verdeil, Grégory ^a   Marquardt, Kristi ^a   Surh, Charles D ^a   Sherman, Linda A ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

CD8 T cells; Cytokine complexes; Interleukin 2; TLR; Tumor immunity

Indexed keywords

CYTOKINE; INTERLEUKIN 2; MONOCLONAL ANTIBODY; TOLL LIKE RECEPTOR;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CELL SURVIVAL; INNATE IMMUNITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; TUMOR GROWTH;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, MONOCLONAL; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; CYTOKINES; IMMUNITY; IMMUNOTHERAPY; IMMUNOTHERAPY, ADOPTIVE; INTERLEUKIN-2; MICE; MICE, TRANSGENIC; NEOPLASMS; POLY I-C; TREATMENT OUTCOME;

EID: 55949105361     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0805054105     Document Type: Article

References (44)

1. Bogen B (1996) Peripheral T cell tolerance as a tumor escape mechanism: Deletion of CD4+ T cells specific for a monoclonal immunoglobulin idiotype secreted by a plasmacytoma. Eur J Immunol 26:2671-2679.
2. Staveley-O'Carroll K, et al. (1998) Induction of antigen-specific T cell anergy: An early event in the course of tumor progression. Proc Natl Acad Sci USA 95:1178-1183.
3. Lyman MA, et al. (2005) The fate of low affinity tumor-specific CD8+ T cells in tumor-bearing mice. J Immunol 174:2563-2572.
4. Guilloux Y, et al. (1994) Defective lymphokine production by most CD8+ and CD4+ tumor-specific T cell clones derived from human melanoma-infiltrating lymphocytes in response to autologous tumor cells in vitro. Eur J Immunol 24:1966-1973.
5. Hernandez J, Lee PP, Davis MM, Sherman LA (2000) The use of HLA A2.1/p53 peptide tetramers to visualize the impact of self tolerance on the TCR repertoire. J Immunol 164:596-602.
6. Gattinoni L, et al. (2005) Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J Exp Med 202:907-912.
7. Rosenberg SA, et al. (1999) Impact of cytokine administration on the generation of antitumor reactivity in patients with metastatic melanoma receiving a peptide vaccine. J Immunol 163:1690-1695.
8. Verdeil G, Puthier D, Nguyen C, Schmitt-Verhulst AM, Auphan-Anezin N (2006) STAT5-mediated signals sustain a TCR-initiated gene expression program toward differentiation of CD8 T cell effectors. J Immunol 176:4834-4842.
9. Malek TR, Bayer AL (2004) Tolerance, not immunity, crucially depends on IL-2. Nat Rev Immunol 4:665-674.
10. Boyman O, Kovar M, Rubinstein MP, Surh CD, Sprent J (2006) Selective stimulation of T cell subsets with antibody-cytokine immune complexes. Science 311:1924-1927.
11. Kamimura D, et al. (2006) IL-2 in vivo activities and antitumor efficacy enhanced by an anti-IL-2 mAb. J Immunol 177:306-314.
12. Rubinstein MP, et al. (2006) Converting IL-15 to a superagonist by binding to soluble IL-15R{alpha}. Proc Natl Acad Sci USA 103:9166-9171.
13. Stoklasek TA, Schluns KS, Lefrancois L (2006) Combined IL-15/IL-15Ralpha immunotherapy maximizes IL-15 activity in vivo. J Immunol 177:6072-6080.
14. Epardaud M, et al. (2008) Interleukin-15/interleukin-15R alpha complexes promote destruction of established tumors by reviving tumor-resident CD8+ T cells. Cancer Res 68:2972-2983.
15. Boyman O, Ramsey C, Kim DM, Sprent J, Surh CD (2008) IL-7/anti-IL7 mAb complexes restore T cell development and induce homeostatic T cell expansion without lymphopenia. J Immunol 180:7265-7275.
16. Jin GH, Hirano T, Murakami M (2008) Combination treatment with IL-2 and anti-IL-2 mAbs reduces tumor metastasis via NK cell activation. Int Immunol 20:783-789.
17. Lyman MA, Aung S, Biggs JA, Sherman LA (2004) A spontaneously arising pancreatic tumor does not promote the differentiation of naive CD8+ T lymphocytes into effector CTL. J Immunol 172:6558-6567.
18. Salem ML, Kadima AN, Cole DJ, Gillanders WE (2005) Defining the antigen-specific T-cell response to vaccination and poly(I:C)/TLR3 signaling: Evidence of enhanced primary and memory CD8 T-cell responses and antitumor immunity. J Immunother 28:220-228.
19. Kumar H, Koyama S, Ishii KJ, Kawai T, Akira S (2008) Cutting edge: Cooperation of IPS-1- and TRIF-dependent pathways in poly IC-enhanced antibody production and cytotoxic T cell responses. J Immunol 180:683-687.
20. Durand V, Wong SY, Tough DF, Le Bon A (2004) Shaping of adaptive immune responses to soluble proteins by TLR agonists: a role for IFN-alpha/beta. Immunol Cell Biol 82:596-602.
21. Hacker G, Bauer A, Villunger A (2006) Apoptosis in activated T cells: What are the triggers, and what the signal transducers? Cell Cycle 5:2421-2424.
22. Sengupta S, Chilton PM, Mitchell TC (2005) Adjuvant-induced survival signaling in clonally expanded T cells is associated with transient increases in pAkt levels and sustained uptake of glucose. Immunobiology 210:647-659.
23. Ozes ON, et al. (1999) NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature 401:82-85.
24. Jones RG, et al. (2000) Protein kinase B regulates T lymphocyte survival, nuclear factor kappaB activation, and Bcl-X(L) levels in vivo. J Exp Med 191:1721-1734.
25. Khoshnan A, et al. (2000) The NF-kappa B cascade is important in Bcl-xL expression and for the anti-apoptotic effects of the CD28 receptor in primary human CD4+ lymphocytes. J Immunol 165:1743-1754.
26. Yoo JK, Cho JH, Lee SW, Sung YC (2002) IL-12 provides proliferation and survival signals to murine CD4+ T cells through phosphatidylinositol 3-kinase/Akt signaling pathway. J Immunol 169:3637-3643.
27. Boyman O, Purton JF, Surh CD, Sprent J (2007) Cytokines and T-cell homeostasis. Curr Opin Immunol 19:320-326.
28. Marrack P, et al. (2000) Homeostasis of alpha beta TCR+ T cells. Nat Immunol 1:107-111.
29. Verdeil G, Chaix J, Schmitt-Verhulst AM, Auphan-Anezin N (2006) Temporal cross-talk between TCR and STAT signals for CD8 T cell effector differentiation. Eur J Immunol 36:3090-3100.
30. Janas ML, Groves P, Kienzle N, Kelso A (2005) IL-2 regulates perforin and granzyme gene expression in CD8+ T cells independently of its effects on survival and proliferation. J Immunol 175:8003-8010.
31. Phelan JD, Orekov T, Finkelman FD (2008) Cutting edge: Mechanism of enhancement of in vivo cytokine effects by anti-cytokine monoclonal antibodies. J Immunol 180:44-48.
32. Kamimura D, Bevan MJ (2007) Naive CD8+ T cells differentiate into protective memory-like cells after IL-2 anti IL-2 complex treatment in vivo. J Exp Med 204:1803-1812.
33. Kieper WC, Burghardt JT, Surh CD (2004) A role for TCR affinity in regulating naive T cell homeostasis. J Immunol 172:40-44.
34. Schluns KS, Kieper WC, Jameson SC, Lefrancois L (2000) Interleukin-7 mediates the homeostasis of naive and memory CD8 T cells in vivo. Nat Immunol 1:426-432.
35. Hou J, et al. (1994) An interleukin-4-induced transcription factor: IL-4 Stat. Science 265:1701-1706.
36. Kaplan MH, Schindler U, Smiley ST, Grusby MJ (1996) Stat6 is required for mediating responses to IL-4 and for development of Th2 cells. Immunity 4:313-319.
37. Ahonen CL, et al. (2004) Combined TLR and CD40 triggering induces potent CD8+ T cell expansion with variable dependence on type I IFN. J Exp Med 199:775-784.
38. Wang L, et al. (2002) Noncoding RNA danger motifs bridge innate and adaptive immunity and are potent adjuvants for vaccination. J Clin Invest 110:1175-1184.
39. Datta SR, et al. (1997) Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 91:231-241.
40. del Peso L, Gonzalez-Garcia M, Page C, Herrera R, Nunez G (1997) Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science 278:687-689.
41. Savill J, Dransfield I, Gregory C, Haslett C (2002) A blast from the past: Clearance of apoptotic cells regulates immune responses. Nat Rev Immunol 2:965-975.
42. Paulos CM, et al. (2007) Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8 T cells via TLR4 signaling. J Clin Invest 117:2197-2204.
43. Morgan DJ, et al. (1996) CD8(+) T cell-mediated spontaneous diabetes in neonatal mice. J Immunol 157:978-983.
44. Martinez X, et al. (2005) CD8+ T cell tolerance in nonobese diabetic mice is restored by insulin-dependent diabetes resistance alleles. J Immunol 175:1677-1685.